Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer
- Conditions
- First Posted Date
- 2004-03-31
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00004097
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer
- Conditions
- First Posted Date
- 2004-03-25
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- UNICANCER
- Registration Number
- NCT00006051
- Locations
- 🇫🇷
Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷CRLCC Nantes - Atlantique, Nantes-Saint Herblain, France
🇫🇷Centre Hospitalier Universitaire Bretonneau de Tours, Tours, France
Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer
- Conditions
- First Posted Date
- 2004-03-24
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- UNICANCER
- Registration Number
- NCT00005944
- Locations
- 🇫🇷
CHR de Besancon - Hopital Jean Minjoz, Besancon, France
🇫🇷Institut Bergonie, Bordeaux, France
🇫🇷Centre Hospitalier Universitaire de Dijon, Dijon, France
A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-03-17
- Last Posted Date
- 2016-06-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1987
- Registration Number
- NCT00009737
Cetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin Chemotherapy
- Conditions
- First Posted Date
- 2004-03-16
- Last Posted Date
- 2009-03-09
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00004865
- Locations
- 🇺🇸
Kimball Medical Center, Lakewood, New Jersey, United States
🇺🇸Monmouth Medical Center, Long Branch, New Jersey, United States
🇺🇸Cooper Cancer Institute, Camden, New Jersey, United States
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2004-03-16
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00004913
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan
- Conditions
- Interventions
- First Posted Date
- 2004-03-11
- Last Posted Date
- 2013-02-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00016978
- Locations
- 🇺🇸
CentraCare Clinic, Saint Cloud, Minnesota, United States
🇺🇸CCOP - Toledo Community Hospital Oncology Program, Toledo, Ohio, United States
🇺🇸Rapid City Regional Hospital, Rapid City, South Dakota, United States
Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer
- Conditions
- First Posted Date
- 2004-03-11
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Scottish Cancer Therapy Network
- Target Recruit Count
- 1000
- Registration Number
- NCT00002580
- Locations
- 🇬🇧
University Hospitals of Leicester, Leicester, England, United Kingdom
🇬🇧Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom
🇬🇧Beatson Oncology Centre, Glasgow, Scotland, United Kingdom
Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer
- Conditions
- First Posted Date
- 2004-03-11
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Scottish Cancer Therapy Network
- Target Recruit Count
- 1000
- Registration Number
- NCT00002581
- Locations
- 🇬🇧
Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom
🇬🇧Beatson Oncology Centre, Glasgow, Scotland, United Kingdom
🇬🇧Ayr Hospital, Ayr, United Kingdom
Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regionally Advanced Unresectable Adenocarcinoma of the Pancreas
- Conditions
- First Posted Date
- 2004-03-10
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- University of South Florida
- Registration Number
- NCT00079365
- Locations
- 🇺🇸
USF Physician's Group, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.